43 research outputs found
Identification of significantly differential endogenous metabolites in the rat kidney.
a<p>Change trend of CRF rats vs control rats.</p>b<p>Change trend of FLP rats vs CRF rats.</p><p>The levels of potential biomarkers were labeled with (↓) down-regulated and (↑) up-regulated (*<i>P</i><0.05; **<i>P</i><0.01; ***<i>P</i><0.001).</p
Basic serum biochemical parameter comparisons among the studied groups.
<p>(A) BUN; (B) Scr; (C) cholesterol; (D) triglyceride. The data were expressed as mean ± SD. *<i>P</i><0.05, **<i>P</i><0.01 compared to the control groups and <sup>#</sup><i>P</i><0.05, <sup>##</sup><i>P</i><0.01 compared to the CKD groups.</p
Basic blood routine parameters of the studied groups.
<p>(A) White blood cell count; (B) red blood cell; (C) hemoglobin and (D) hematocrit. The data were expressed as mean ± SD. *<i>P</i><0.05, **<i>P</i><0.01 compared to the control groups and <sup>#</sup><i>P</i><0.05, <sup>##</sup><i>P</i><0.01 compared to the CKD groups.</p
Correlation coefficient analysis between groups with corresponding markers in different groups.
<p>Variables are presented in control, CKD and FLP groups. Values of correlations are shown in the vertical axis (upper for positive correlations and low for negative correlations) and corresponding markers represented to the right of the bars. Numbers are consistent with <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0059617#pone-0059617-t001" target="_blank">Table 1</a>.</p
PLS-DA scores plots (A) and Loading plots (B) derived from UPLC-MS data of serum samples.
<p>(▴) control group, (•) CKD group and (♦) FLP-treated group. The variables marked (□) are the metabolites selected as potential biomarkers.</p
Physical parameter comparisons among the studied groups.
<p>(A) Body weight; (B) urinary volume and (C) kidney weight index. The data were expressed as mean ± SD. *<i>P</i><0.05, **<i>P</i><0.01 compared to the control groups and <sup>#</sup><i>P</i><0.05, <sup>##</sup><i>P</i><0.01 compared to the CKD groups.</p
Fluorescence microscopy images of MCF-7, MDA-MB-231 and HepG2 Cells.
<p>Different cells were treated with 20 µM of DOX (a1,b1,c1), PEG-ami-DOX (a2,b2,c2), and PEG-hyd-DOX (c1,c2,c3) for 30 min, repectively. From left to right, there were images of DOX or its conjugates (red dots), DAPI staining for nucleus (blue dots) and their merged images.</p
Plasma concentration-time curves of DOX, PEG-ami-DOX and PEG-hyd-DOX after i.v. administration to female tumor-bearing mice at the same 5 mg/kg DOX dose.
<p>(n = 5, mean ± SD).</p
Intracellular DOX levels assayed by LC/MS/MS.
<p>After treatment by PEG-DOX conjugates (20 µM DOX. Eq) or DOX in MDA-MB-231 (left), MCF-7 (middle) or HepG2 cells (right) for 2, 4 and 8 h respectively. (<sup>*</sup><i>p</i><0.05, <sup>**</sup><i>p</i><0.01, PEG-hyd-DOX <i>vs</i> DOX; <sup># </sup><i>p</i><0.05, PEG-hyd-DOX <i>vs</i> PEG-ami-DOX, n = 4, mean ± SD).</p
The HepG2 cells apoptosis induced by resveratrol and piceid.
*<p>P<0.05 <i>vs</i> control,</p>**<p>P<0.01 <i>vs</i> control, n = 3.</p